Main findings
We observed that HFrEF patients on optimal medical therapy did not benefit from additional years of extended follow-up in a specialized HF clinic. The risk of relevant HF endpoints and adherence to neurohormonal blockade did not differ between patients followed in an HFC compared to PC. Our results underscore the need for the development of improved monitoring programs to improve outcomes for patients receiving guideline-directed therapy.